Shanghai Engineering Research Center of Anti-tumor Biological Drugs, Shanghai Henlius Biotech, Inc., Shanghai, China.
Key Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China.
Biotechnol J. 2022 Nov;17(11):e2100351. doi: 10.1002/biot.202100351. Epub 2022 Aug 7.
The biopharmaceutical market is driving the revolution from traditional batch processes to continuous manufacturing for higher productivity and lower costs. In this work, a batch mAb downstream process has been converted into an integrated continuous process with the combination of multiple techniques. For process intensification, two batch mode unit operations (protein A capture chromatography, ultrafiltration/diafiltration) were converted into continuous ones; for continuity, surge tanks were used between adjacent steps, and level signals were used to trigger process start or stop, forming a holistic continuous process. For process automation, manual operations (e.g., pH and conductivity adjustment) were changed into automatic operation and load mass was controlled with process analytical technology (PAT). A model-based simulation was applied to estimate the loading conditions for the continuous capture process, resulting in 21% resin capacity utilization and 28% productivity improvement as compared to the batch process. Automatic load mass control of cation exchange chromatography (CEX) was achieved through a customized in-line protein quantity monitoring system, with a difference of less than 1.3% as compared to off-line analysis. Total process time was shortened from 4 days (batch process) to less than 24 hours using the continuous downstream process with the overall productivity of 23.8 g mAb per day for the bench-scale system. Comparable yield and quality data were obtained in three test runs, indicating a successful conversion from a batch process to a continuous process. The insight of this work could be a reference to other similar situations.
生物制药市场正在推动从传统批处理工艺向连续制造的转变,以提高生产力和降低成本。在这项工作中,通过多种技术的结合,将单抗的批处理下游工艺转化为集成的连续工艺。为了强化工艺,将两种批处理模式的单元操作(蛋白 A 捕获层析、超滤/渗滤)转化为连续操作;为了保持连续性,在相邻步骤之间使用了缓冲罐,通过液位信号触发工艺的启动或停止,形成一个整体的连续工艺。为了实现自动化,将手动操作(例如 pH 和电导率调节)改为自动操作,并采用过程分析技术(PAT)控制加载质量。通过基于模型的模拟来估算连续捕获工艺的加载条件,与批处理工艺相比,树脂利用率提高了 21%,生产率提高了 28%。通过定制的在线蛋白质定量监测系统实现了阳离子交换层析(CEX)的自动加载质量控制,与离线分析相比,差异小于 1.3%。使用连续的下游工艺,总工艺时间从 4 天(批处理工艺)缩短到不到 24 小时,对于 bench-scale 系统,每天的单抗总体生产率达到 23.8 g。在三次测试运行中获得了可比的收率和质量数据,表明从批处理工艺成功转化为连续工艺。这项工作的启示可以为其他类似情况提供参考。